{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:13:50Z","timestamp":1762460030965,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jdiacomp.2021.108046","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T17:27:11Z","timestamp":1631467631000},"page":"108046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria"],"prefix":"10.1016","volume":"35","author":[{"given":"Christoph H.","family":"Saely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Maechler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Vonbank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Zanolin-Purin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Leiherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Muendlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2021.108046_bb0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney disease: improving global outcomes chronic kidney disease guideline development work group members. evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0010","doi-asserted-by":"crossref","first-page":"F1589","DOI":"10.1152\/ajprenal.00142.2008","article-title":"Disease-dependent mechanisms of albuminuria","volume":"295","author":"Comper","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0015","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0020","doi-asserted-by":"crossref","DOI":"10.4172\/2167-7662.1000118","article-title":"Association of microalbuminuria with ischemic heart disease, dyslipidemia and obesity among diabetic patients: experience from 5 year follow up study of 1415 patients","volume":"03","author":"MA Aziz","year":"2014","journal-title":"Bioenerg Open Access"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.109.881805","article-title":"Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-heart failure trial","volume":"3","author":"Masson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cardfail.2015.10.009","article-title":"Prevalence of albuminuria in a general population cohort of patients with established chronic heart failure","volume":"22","author":"Odutayo","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0045","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0050","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1161\/01.CIR.90.5.2230","article-title":"Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis","volume":"90","author":"Drexel","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0065","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/0886022X.2016.1138837","article-title":"Albuminuria in type 2 diabetes mellitus: from remission to progression","volume":"38","author":"Bentata","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1755-6686.2010.00165.x","article-title":"The diabetic CKD patient\u2013a major cardiovascular challenge","volume":"36","author":"van der Meer","year":"2010","journal-title":"J Ren Care"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0085","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/ehjci\/jex231","article-title":"Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes","volume":"19","author":"Jorgensen","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabet.2010.12.006","article-title":"Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease","volume":"37","author":"Nguyen","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: effects on the cardiovascular system","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0100","first-page":"13","article-title":"Proteinuria and its relation to cardiovascular disease","volume":"7","author":"Currie","year":"2013","journal-title":"Int J Nephrol Renov Dis"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00125-008-0961-8","article-title":"What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?","volume":"51","author":"Satchell","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2013.02.005","article-title":"Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II","volume":"378","author":"Nistala","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0115","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","article-title":"The role of the kidney in heart failure","volume":"33","author":"Metra","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0120","article-title":"Albuminuria: associated with heart failure severity and impaired clinical outcomes","author":"Shuvy","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1479164113500798","article-title":"Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register","volume":"10","author":"Svensson","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2017.4228","article-title":"Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the","volume":"3","author":"Scirica","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cardfail.2003.09.003","article-title":"Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes","volume":"10","author":"Hockensmith","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0145","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose Cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0150","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a posthoc analysis from the CREDENCE trial","author":"Oshima","year":"2020","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/dom.12600","article-title":"Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0165","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0175","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0180","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0185","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0190","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0195","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - results from the EMPEROR-reduced trial","author":"Anker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108046_bb0200","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721002609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721002609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:14:09Z","timestamp":1761005649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872721002609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1056872721002609"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.108046","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.108046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021","name":"copyright","label":"Copyright"}],"article-number":"108046"}}